New oncology trial designs and equipoise: Commentary on Heynemann et al.
Jonathan Kimmelman · 2026
Read New oncology trial designs and equipoise: Commentary on Heynemann et al. by Jonathan Kimmelman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624336.txt.
Description
Jonathan Kimmelman argued in 2026, in a commentary on new cancer trial designs, that the old ethical yardstick of equipoise fits the new designs as well as the old. Equipoise means honest uncertainty in the expert community about which arm of a trial is better. New designs, such as adaptive and platform trials, were said to strain that idea.
Kimmelman flips the charge. Equipoise, he argues, pushes designers to run trials exactly where uncertainty is greatest. That maximizes what each enrolled patient teaches and minimizes burden per unit of knowledge. So equipoise is not an obstacle the new designs must escape. It is a condition they must satisfy, and a challenge to their inventors. The essay closes by reversing the burden of proof onto the designers.
Catalog record
| CREATOR | Jonathan Kimmelman |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |